Tiotropium — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Asthma / Acute Bronchospasm

• Albuterol
• Budesonide
• Fluticasone
• Ipratropium
• Montelukast
• Salmeterol

Also listed for COPD

• Albuterol HFA
• Albuterol HFA 90 mcg inhaler

Other medications in Respiratory

• Treprostinil Oral
• Zafirlukast
• Zileuton
• Cromolyn Sodium Inhaler
• Theophylline ER

About Tiotropium

Living with a chronic respiratory condition like COPD can be challenging, but medications like tiotropium offer a path to clearer breathing and improved quality of life. As a long-acting bronchodilator, tiotropium plays a vital role in managing symptoms. The good news?

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Tiotropium is approved for (FDA label)

Tiotropium bromide inhalation powder is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Tiotropium bromide inhalation powder is indicated to reduce exacerbations in COPD patients. Tiotropium bromide inhalation powder is an anticholinergic indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: November 11, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Tiotropium (FDA label)

Inhalation Powder: Tiotropium bromide inhalation powder consists of tiotropium bromide inhalation powder capsules containing tiotropium powder for oral inhalation and a LupinHaler device. Tiotropium bromide inhalation powder capsules contain 18 mcg of tiotropium (equivalent to 22.5 mcg tiotropium bromide monohydrate USP) in a hypromellose capsule with white opaque cap and white opaque body, imprinted with "LU" on cap and "T18" on body. The LupinHaler device is only intended for use with the tiotropium bromide inhalation powder capsules. Inhalation powder: Tiotropium bromide inhalation powder capsules contain 18 mcg tiotropium powder (equivalent to 22.5 mcg tiotropium bromide monohydrate USP) for use with LupinHaler device ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 496b38ee-45b6-4bb2-a35e-9023c3b73719. SPL document ID: 87de16e4-1447-4bf6-90f6-705829efe684. Label effective date: November 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Tiotropium (FDA label)

The following adverse reactions are described, or described in greater detail, in other sections: Immediate hypersensitivity reactions [see Warnings and Precautions ( 5.2 )] Paradoxical bronchospasm [see Warnings and Precautions ( 5.3 )] Worsening of narrow-angle glaucoma [see Warnings and Precautions ( 5.4 )] Worsening of urinary retention [see Warnings and Precautions ( 5.5 )] The most common adverse reactions (>5% incidence in the 1-year placebo- controlled trials) were upper respiratory tract infection, dry mouth, sinusitis, pharyngitis, non-specific chest pain, urinary tract infection, dyspepsia, and rhinitis ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the incidence of adverse reactions observed in the clinical trials of a drug cannot be directly compared to the incidences in the clinical trials of another drug and may not reflect the incidences observed in practice. 6-Month to 1-Year Trials The data described below reflect exposure to tiotropium bromide inhalation powder in 2,663 patients.

Source: FDA prescribing information (DailyMed). Set ID: 496b38ee-45b6-4bb2-a35e-9023c3b73719. SPL document ID: 87de16e4-1447-4bf6-90f6-705829efe684. Label effective date: November 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Tiotropium (FDA label)

Tiotropium bromide inhalation powder is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any components of this product [see Warnings and Precautions ( 5.2 )] . In clinical trials and postmarketing experience with tiotropium bromide inhalation powder, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see Warnings and Precautions ( 5.2 )] . Hypersensitivity to tiotropium, ipratropium, or any components of tiotropium bromide inhalation powder capsules ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 496b38ee-45b6-4bb2-a35e-9023c3b73719. SPL document ID: 87de16e4-1447-4bf6-90f6-705829efe684. Label effective date: November 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Tiotropium (FDA label)

Not for acute use: Not a rescue medication ( 5.1 ) Immediate hypersensitivity reactions: Discontinue tiotropium bromide inhalation powder at once and consider alternatives if immediate hypersensitivity reactions, including angioedema, urticaria, rash, bronchospasm, or anaphylaxis, occur. Use with caution in patients with severe hypersensitivity to milk proteins. ( 5.2 ) Paradoxical bronchospasm: Discontinue tiotropium bromide inhalation powder and consider other treatments if paradoxical bronchospasm occurs ( 5.3 ) Worsening of narrow-angle glaucoma may occur. Use with caution in patients with narrow-angle glaucoma and instruct patients to consult a physician immediately if this occurs. ( 5.4 ) Worsening of urinary retention may occur.

Source: FDA prescribing information (DailyMed). Set ID: 496b38ee-45b6-4bb2-a35e-9023c3b73719. SPL document ID: 87de16e4-1447-4bf6-90f6-705829efe684. Label effective date: November 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Tiotropium (FDA label)

Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of tiotropium bromide inhalation powder with other anticholinergic-containing drugs. ( 7.2 ) 7.1 Sympathomimetics, Methylxanthines, Steroids Tiotropium bromide inhalation powder has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, and oral and inhaled steroids without increases in adverse reactions. 7.2 Anticholinergics There is potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid coadministration of tiotropium bromide inhalation powder with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see Warnings and Precautions ( 5.4 , 5.5 ) and Adverse Reactions ( 6 )].

Source: FDA prescribing information (DailyMed). Set ID: 496b38ee-45b6-4bb2-a35e-9023c3b73719. SPL document ID: 87de16e4-1447-4bf6-90f6-705829efe684. Label effective date: November 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.